Nanoscan (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanoscan, is a plasma protein presented as a sterile injectable solution for intravenous use. It is employed to restore oncotic pressure and volume in patients with hypoalbuminemia, burns, trauma, or during major surgery.

GNH USA supplies Nanoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and critical‑care units worldwide.

Nanoscan (human serum albumin) is used as a plasma volume expander in conditions characterized by low oncotic pressure or protein loss.

Hypoalbuminemia: restores serum albumin levels and improves oncotic pressure. Burn injuries: provides volume expansion and protein replacement in severe burns. Major surgery: maintains circulatory volume and supports hemodynamic stability. Chronic liver disease: corrects low albumin concentrations in patients with hepatic insufficiency.

Adverse reactions may occur with intravenous human serum albumin administration.

Common Side Effects: - Fever or chills - Mild hypotension - Headache - Nausea or vomiting - Rash or urticaria - Transient hypertension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Volume overload leading to pulmonary edema - Hemolysis - Acute kidney injury - Transmission of infectious agents (theoretical risk) - Severe hypotension or shock

Human serum albumin should be used with attention to patient‑specific factors and monitoring. - Allergy assessment: verify no known hypersensitivity to albumin or blood products. - Volume status: evaluate for risk of fluid overload, especially in cardiac or renal failure. - Cardiac monitoring: observe for signs of congestive heart failure during infusion. - Renal function: adjust infusion rate in patients with impaired kidney function. - Co‑administration with diuretics: monitor fluid balance closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Albumin can influence the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Concurrent volume expanders: may precipitate fluid overload. - High‑dose diuretics: increase risk of hypovolemia. - Certain anticoagulants (e.g., warfarin): altered plasma protein binding may affect anticoagulant effect.

Moderate Interactions (Monitor Closely): - Drugs highly bound to albumin (e.g., phenytoin, valproic acid): monitor serum levels. - Antibiotics such as penicillins: potential displacement leading to increased free drug. - ACE inhibitors or ARBs: watch for additive hypotensive effects.